MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

NCT04651634 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Oral Mucositis

Interventions

DRUG: MIT-001 plus CCRT

Sponsor

MitoImmune Therapeutics